Bifogade filer
251110 EXPRS2 PR Malaria Program Update
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Global Context: The Fight Against Malaria
Malaria remains a leading cause of illness and death worldwide. In 2023, there were an estimated 263 million malaria cases and 597,000 deaths, mostly in sub-Saharan Africa (World Health Organization, World Malaria Report 2024). Despite progress in prevention and treatment, new vaccine approaches are urgently required to achieve lasting control of the disease.
ExpreS2ion and the University of Oxford (“Oxford”) have collaborated for several years on malaria vaccine development using ExpreS2ion’s proprietary protein expression system, ExpreS2. This system enables consistent and scalable production of high-quality malaria antigens for both transmission-blocking and blood-stage vaccines, supporting Oxford’s efforts to address multiple points in the parasite’s lifecycle.
Program Update: Oxford Malaria Vaccine Trials Using ExpreS2ion’s Platform
Oxford’s malaria research network continues to advance several vaccine candidates produced using ExpreS2ion’s ExpreS2 platform. These candidates target distinct stages of the malaria parasite’s lifecycle and are progressing through multiple clinical studies.
As of the third quarter of 2025, ten Oxford-led malaria vaccine studies using ExpreS2ion’s ExpreS2 platform remain active. Six are in Phase I, focused on safety, tolerability, and early immune response assessments. Four are in Phase II, assessing the strength and durability of immune responses and early signals of efficacy. Together, these studies illustrate coordinated progress in evaluating next-generation malaria vaccines produced through a single, reliable recombinant protein system.
Several readouts are expected from late 2025 through 2027 as studies complete analysis and review. One early Oxford study concluded in March 2025 and is not included in the active count.
Quarter-over-Quarter Changes (Q2–Q3 2025)
Verified updates from the third quarter of 2025 show continued advancement across Oxford’s malaria vaccine portfolio:
- Two studies reached full recruitment status, moving toward data analysis.
- Two new studies began recruitment, with completion targeted for late 2026 and mid-2027.
- Overall, ten ExpreS2ion-supported malaria vaccine studies remain active across multiple phases of clinical evaluation.
An overview will be provided in the Q3 Report, which is released on 13 November.
Investor Relevance: Potential Value Creation
The continued advancement of the Oxford malaria vaccine portfolio further supports the potential validation of ExpreS2ion’s ExpreS2 platform in human clinical settings. Positive results from these studies could strengthen ExpreS2ion’s position in ongoing and future research collaborations and may, under suitable conditions, lead to milestone or licensing income. However, potential commercial arrangements are expected to follow the conventions of global health partnerships, where revenues are typically modest and linked to publicly funded access programs.
Ongoing collaboration with Oxford also expands the visibility of ExpreS2ion’s technology across global health programs that depend on scalable vaccine manufacturing solutions. While ExpreS2ion is not the trial sponsor and outcomes remain subject to external factors, the progress of these programs reinforces the Company’s strategic relevance in next-generation vaccine development.
Most lately, University of Oxford, acting as the project coordinator, and a consortium of leading research institutions in Africa and Europe, that include ExpreS2ion, has been awarded a 15 million EUR grant under the Horizon Europe scheme in the 2nd Generation Malaria Vaccine Consortium (MVC-2G), to advance a plasmodium falciparum malaria vaccine. The grant funds clinical investigations, including in Phase IIb settings, of the current WHO recommended malaria vaccine R21/Matrix-M in combination with Matrix-M-formulated antigens RH5.1 and R78C, both of which are manufactured based on the ExpreS2 platform. The Horizon Europe program is primarily research-focused and not designed to generate direct commercial revenue for consortium participants. Instead, it enhances scientific collaboration, visibility, and validation opportunities for the ExpreS2 platform.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB